.After increasing $170 thousand back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on everyone market.The Eli Lilly-partnered biotech plan to list on the Nasdaq under the icon “BIOA,” depending on to papers submitted with the Stocks and Swap Commission. The provider has not openly discussed an assumed monetary volume for the offering.The clinical-stage provider proclaims lead prospect azelaprag, an orally provided little molecule slated to go into phase 2 screening in combination along with semaglutide– marketed through Novo Nordisk under brand Wegovy for weight management– in the initial fifty percent of following year. Semaglutide is additionally marketed as Ozempic and also Rybelsus by Novo for diabetes.
Apelin receptor agonist azelaprag is designed to mix properly with GLP-1 medicines, boosting weight reduction while keeping muscle mass. The investigational medicine was actually located to become well-tolerated among 265 individuals all over eight stage 1 trials, according to BioAge.Previously, BioAge achieved the help of Lilly to manage a test blending azelaprag along with the Significant Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is actually industried for diabetes mellitus as Mounjaro and Zepbound for fat burning. The partners are currently conducting a period 2 test of azelaprag as well as tirzepatide, along with topline outcomes expected in the third quarter of 2025.The biotech is actually additionally preparing a blood insulin level of sensitivity proof-of-concept trial analyzing azelaprag as a monotherapy in the 1st fifty percent of upcoming year to support prospective evidence expansion.
On top of that, the provider plans to inquire the FDA for consent in the 2nd fifty percent of 2025 to release human screening for an NLRP3 prevention targeting metabolic conditions as well as neuroinflammation.BioAge’s expected move to the general public market complies with a slight uptick in intended biotech IPOs from Bicara Therapies and also Zenas Biopharma. Zooming out, the current IPO garden is a “mixed image,” with high-grade companies still debuting on everyone markets, just in lessened numbers, depending on to PitchBook.